Dr. rer. nat. Thomas Kammertöns

University Education

• 1989-1996 Biology und North American Studies, FU Berlin
• 1994-1995 Fulbright scholarship, Vanderbilt University, USA
• 1996-2001 Ph.D., MDC

Professional Experience (selection)

• 2001-2004 Staff scientist at the MDC
• Since 2004 Staff scientist at the Institute of Immunology, Charité

Research Fields

• i)    Tumor immunology
• ii)   Immunology
• iii)  Gene therapy

Most important Awards, Grants or Scientific Achievements

• PI Research Training Group SFB/TRR 36, PI Project B1 SFB/TRR 36

Selected References

• Gloger, M., Menzel, L., Grau, M., Vion, A. C., Anagnostopoulos, I., Zapukhlyak, M., Gerlach, K., Kammertöns, T., Hehlgans, T., Zschummel, M., Lenz, G., Gerhardt, H., Höpken, U. E., & Rehm, A. (2020). Lymphoma Angiogenesis Is Orchestrated by Noncanonical Signaling Pathways. Cancer research, 80(6), 1316–1329.
• Walsh, J. T., Hendrix, S., Boato, F., Smirnov, I., Zheng, J., Lukens, J. R., Gadani, S., Hechler, D., Gölz, G., Rosenberger, K., Kammertöns, T., Vogt, J., Vogelaar, C., Siffrin, V., Radjavi, A., Fernandez-Castaneda, A., Gaultier, A., Gold, R., Kanneganti, T. D., Nitsch, R., … Kipnis, J. (2015). MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4. The Journal of clinical investigation, 125(2), 699–714.
• Kammertoens, T., Friese, C., Arina, A., Idel, C., Briesemeister, D., Rothe, M., Ivanov, A., Szymborska, A., Patone, G., Kunz, S., Sommermeyer, D., Engels, B., Leisegang, M., Textor, A., Fehling, H. J., Fruttiger, M., Lohoff, M., Herrmann, A., Yu, H., Weichselbaum, R., … Blankenstein, T. (2017). Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature, 545(7652), 98–102.
• Leisegang, M., Kammertoens, T., Uckert, W., & Blankenstein, T. (2016). Targeting human melanoma neoantigens by T cell receptor gene therapy. The Journal of clinical investigation, 126(3), 854–858.
• Listopad, J. J., Kammertoens, T., Anders, K., Silkenstedt, B., Willimsky, G., Schmidt, K., Kuehl, A. A., Loddenkemper, C., & Blankenstein, T. (2013). Fas expression by tumor stroma is required for cancer eradication. Proceedings of the National Academy of Sciences of the United States of America, 110(6), 2276–2281.
• Kammertoens, T., & Blankenstein, T. (2013). It's the peptide-MHC affinity, stupid. Cancer cell, 23(4), 429–431.
• Anders, K., Buschow, C., Herrmann, A., Milojkovic, A., Loddenkemper, C., Kammertoens, T., Daniel, P., Yu, H., Charo, J., & Blankenstein, T. (2011). Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer cell, 20(6), 755–767.
• Nassenstein, C., Kammertoens, T., Veres, T. Z., Uckert, W., Spies, E., Fuchs, B., Krug, N., & Braun, A. (2007). Neuroimmune crosstalk in asthma: dual role of the neurotrophin receptor p75NTR. The Journal of allergy and clinical immunology, 120(5), 1089–1096.
• Kammertoens, T., Schüler, T., & Blankenstein, T. (2005). Immunotherapy: target the stroma to hit the tumor. Trends in molecular medicine, 11(5), 225–231.
• Stelljes, M., Strothotte, R., Pauels, H. G., Poremba, C., Milse, M., Specht, C., Albring, J., Bisping, G., Scheffold, C., Kammertoens, T., Oelmann, E., Silling, G., Berdel, W. E., & Kienast, J. (2004). Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets. Blood, 104(4), 1210–1216.
• Schüler, T., Kammertoens, T., Preiss, S., Debs, P., Noben-Trauth, N., & Blankenstein, T. (2001). Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8(+) T cells. The Journal of experimental medicine, 194(12), 1767–1775.
• Beltinger, C., Fulda, S., Kammertoens, T., Meyer, E., Uckert, W., & Debatin, K. M. (1999). Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proceedings of the National Academy of Sciences of the United States of America, 96(15), 8699–8704.